Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Overcoming barriers to early disease intervention

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Differences in primary prevention, secondary prevention and early disease intervention, depicting target groups, goals and examples for each approach.
Fig. 2: Hypothetical illustrative example of integrated early disease intervention paradigm.


  1. Anonymous. Nat. Biotechnol. 37, 197 (2019).

  2. Bluestone, J. A., Herold, K. & Eisenbarth, G. Nature 464, 1293–1300 (2010).

    Article  CAS  Google Scholar 

  3. Diabetes Prevention Trial–Type 1 Diabetes Study Group. N. Engl. J. Med. 346, 1685–1691 (2002).

  4. Egan, M. F. et al. N. Engl. J. Med. 380, 1408–1420 (2019).

    Article  CAS  Google Scholar 

  5. Demongeot, J. et al. Int. J. Mol. Sci. 10, 4437–4473 (2009).

    Article  CAS  Google Scholar 

  6. Foust, K. D. et al. Nat. Biotechnol. 28, 271–274 (2010).

    Article  CAS  Google Scholar 

  7. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Nat. Rev. Neurol. 14, 214–224 (2018).

    Article  Google Scholar 

  8. Dominguez, E. et al. Hum. Mol. Genet. 20, 681–693 (2011).

    Article  CAS  Google Scholar 

  9. US Food and Drug Administration. (2019).

  10. Hickey, R. D. et al. Cell Transplant. 28, 79–88 (2019).

    Article  Google Scholar 

  11. Herold, K. C. et al. N. Engl. J. Med. 381, 603–613 (2019).

    Article  CAS  Google Scholar 

  12. Korde, N. et al. JAMA Oncol. 1, 746–754 (2015).

    Article  Google Scholar 

  13. Landgren, O. et al. Leukemia 33, 2127–2143 (2019).

    Article  CAS  Google Scholar 

  14. Zhao, A. L. et al. Cancer Manag. Res. 11, 5599–5611 (2019).

    Article  CAS  Google Scholar 

  15. Pentland, A. Social Physics Vol. 1 (Penguin, 2015).

Download references


Our perspective has benefited from a global network of colleagues. In particular, it has been challenged, informed and enriched by conversations with many people, including R. Hendricks, D. Blumenthal, B. Wiegand, K. Wildenhaus, J. Hedrick, S. Brady, G. Pigino, J. M. Peyrin, P. Prieto, J. Fleming and A. Zarur.

Author information

Authors and Affiliations


Corresponding author

Correspondence to H. Hugo Caicedo.

Ethics declarations

Competing interests

D.A.H. consults for Johnson & Johnson, Verily Life Sciences, and Worrell. He has received research support from Olympus. A.P. is on the Advisory Boards of Pear Therapeutics. G.P.P. consults for Johnson & Johnson, Takeda, Bristol-Myers Squibb, Eli Lilly and Tolero, and serves on the Board of Directors of Axcella Health and Celixir.

Additional information

Editorial note: This article has been peer reviewed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caicedo, H.H., Hashimoto, D.A., Caicedo, J.C. et al. Overcoming barriers to early disease intervention. Nat Biotechnol 38, 669–673 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research